Загрузка...
Effect of CYP3A4(∗)1G and CYP3A5(∗)3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects
Ticagrelor is the first reversible, direct-acting, potent P2Y(12) receptor antagonist in management of acute coronary syndromes. It is rapidly absorbed and extensively metabolized. AR-C124910XX, the major active metabolite, antagonizes the P2Y(12) receptor at approximately equal potency. The metabol...
Сохранить в:
| Опубликовано в: : | Front Pharmacol |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5374142/ https://ncbi.nlm.nih.gov/pubmed/28408884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00176 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|